Biotec Services International Completes its Rebrand into PCI
PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group.
PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group. This rebrand expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products and include manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
